Gagnon Securities LLC reduced its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,131 shares of the biopharmaceutical company’s stock after selling 60 shares during the period. Gagnon Securities LLC’s holdings in Vanda Pharmaceuticals were worth $296,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in VNDA. State Street Corp raised its stake in shares of Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock worth $27,935,000 after buying an additional 374,095 shares in the last quarter. Cheyne Capital Management UK LLP boosted its position in Vanda Pharmaceuticals by 42.3% in the first quarter. Cheyne Capital Management UK LLP now owns 74,000 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 22,000 shares during the last quarter. Weiss Multi Strategy Advisers LLC boosted its position in Vanda Pharmaceuticals by 20.0% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 10,000 shares during the last quarter. FMR LLC boosted its position in Vanda Pharmaceuticals by 928.0% in the fourth quarter. FMR LLC now owns 996,271 shares of the biopharmaceutical company’s stock worth $15,891,000 after buying an additional 899,358 shares during the last quarter. Finally, Prudential Financial Inc. boosted its position in Vanda Pharmaceuticals by 0.8% in the first quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock worth $8,600,000 after buying an additional 4,700 shares during the last quarter. 91.35% of the stock is owned by hedge funds and other institutional investors.
Shares of Vanda Pharmaceuticals Inc. (VNDA) traded down 0.484% during trading on Wednesday, reaching $15.425. 161,571 shares of the company’s stock traded hands. The company has a 50 day moving average price of $15.89 and a 200 day moving average price of $14.60. Vanda Pharmaceuticals Inc. has a 1-year low of $11.41 and a 1-year high of $18.00. The stock’s market capitalization is $687.21 million.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.04. The company had revenue of $37.42 million for the quarter, compared to analyst estimates of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. On average, equities analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.70) EPS for the current fiscal year.
VNDA has been the topic of a number of recent analyst reports. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $23.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. HC Wainwright initiated coverage on shares of Vanda Pharmaceuticals in a research report on Friday, May 26th. They issued a “buy” rating and a $18.00 target price on the stock. CIBC reaffirmed an “outperform” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Finally, TheStreet raised shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.22.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
